Go Pro
→ Trump Takes Emergency Action - Plus Elon Musk's New Venture (From Altimetry) (Ad)tc pixel Free RMD Stock Alerts

ResMed (RMD) Financials

ResMed logo
$240.03 -0.30 (-0.12%)
As of 08/31/2026 03:58 PM Eastern
Compare
Annual Income Statements for ResMed

Annual Income Statements for ResMed

This table shows ResMed's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 352 342 316 405 622 475 779 898 1,021 1,401 1,523
Consolidated Net Income / (Loss)		 352 342 316 405 622 475 779 898 1,021 1,401 1,523
Net Income / (Loss) Continuing Operations		 352 342 316 405 622 475 779 898 1,021 1,401 1,523
Total Pre-Tax Income 		440 419 521 519 733 884 960 1,102 1,265 1,678 1,919
Total Operating Income		 429 426 542 579 810 904 1,000 1,132 1,320 1,685 1,887
Total Gross Profit		 1,066 1,202 1,335 1,494 1,718 1,839 2,024 2,356 2,655 3,055 3,452
Total Revenue		 1,839 2,067 2,340 2,607 2,957 3,197 3,578 4,223 4,685 5,146 5,653
Operating Revenue		 1,839 2,067 2,340 2,607 2,957 3,197 3,578 4,223 4,685 - 5,653
Total Cost of Revenue		 772 865 1,005 1,113 1,239 1,358 1,554 1,867 2,030 2,091 2,202
Operating Cost of Revenue		 772 865 1,005 1,113 1,239 1,358 1,554 1,867 2,030 2,091 2,202
Total Operating Expenses		 638 776 793 915 908 935 1,024 1,224 1,335 1,370 1,565
Selling, General & Admin Expense		 488 554 600 645 677 670 738 874 917 993 1,120
Research & Development Expense		 119 144 155 181 202 225 254 288 308 331 378
Amortization Expense		 24 47 19 32 30 31 31 42 47 45 45
Restructuring Charge		 6.91 22 18 9.40 0.00 8.67 1.86 20 64 0.00 22
Total Other Income / (Expense), net		 11 -7.06 -21 -60 -77 -20 -40 -30 -55 -7.80 33
Interest & Investment Income		 17 17 16 -14 -25 -11 -31 -55 -48 3.64 57
Other Income / (Expense), net		 4.96 4.10 -8.54 -11 -12 15 -9.01 24 -7.54 -16 -24
Income Tax Expense		 87 76 206 114 111 409 181 204 244 277 396
Basic Earnings per Share		 $2.51 $2.42 $2.21 $2.83 $4.31 $3.27 $5.34 $6.12 $6.94 $9.55 $10.47
Weighted Average Basic Shares Outstanding		 140.24M 141.36M 142.76M 143.11M 144.34M 145.31M 146.07M 146.77M 147.02M 146.72M 145.52M
Diluted Earnings per Share		 $2.49 $2.40 $2.19 $2.80 $4.27 $3.24 $5.30 $6.09 $6.92 $9.51 $10.43
Weighted Average Diluted Shares Outstanding		 141.67M 142.45M 143.99M 144.48M 145.65M 146.45M 147.04M 147.46M 147.55M 147.34M 146.05M
Weighted Average Basic & Diluted Shares Outstanding		 140.40M 141.40M 142.80M 143M 144.90M 145.68K 146.42M 147.07M 146.93M 146.41M 144.25M
Cash Dividends to Common per Share		 $1.20 $1.32 $1.40 $1.48 $1.56 $1.56 $1.68 $1.76 $1.92 $2.12 $2.40

Quarterly Income Statements for ResMed

This table shows ResMed's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 Q4 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 209 300 292 311 345 365 380 349 393 399 383
Consolidated Net Income / (Loss)		 209 300 292 311 345 365 380 349 393 399 383
Net Income / (Loss) Continuing Operations		 209 300 292 311 345 365 380 349 393 399 383
Total Pre-Tax Income 		259 375 358 383 418 418 458 447 496 502 474
Total Operating Income		 275 375 381 387 417 426 455 447 492 500 449
Total Gross Profit		 647 693 716 717 751 766 820 821 879 891 861
Total Revenue		 1,163 1,197 1,223 1,225 1,282 1,292 1,348 1,336 1,423 1,431 1,464
Operating Revenue		 1,163 1,197 1,223 - - - - 1,336 1,423 1,431 1,464
Total Cost of Revenue		 516 504 508 507 531 525 528 515 544 540 602
Operating Cost of Revenue		 516 504 508 507 531 525 528 515 544 540 602
Total Operating Expenses		 372 318 334 330 334 340 366 374 387 391 413
Selling, General & Admin Expense		 222 230 242 239 242 245 265 259 278 286 296
Research & Development Expense		 74 77 81 80 81 84 86 87 91 94 106
Amortization Expense		 12 11 11 11 11 11 12 12 12 11 10
Total Other Income / (Expense), net		 -16 0.84 -23 -3.82 1.08 -8.58 3.51 0.26 4.49 2.50 25
Interest & Investment Income		 -13 -11 -45 0.96 1.08 0.34 1.27 10 9.46 14 23
Other Income / (Expense), net		 -2.57 11 -18 -3.12 0.78 -9.70 -3.51 -10 -4.98 -12 2.34
Income Tax Expense		 51 75 65 72 74 53 78 98 104 104 91
Basic Earnings per Share		 $1.42 $2.04 $1.99 $2.12 $2.35 $2.49 $2.59 $2.38 $2.69 $2.74 $2.66
Weighted Average Basic Shares Outstanding		 147.13M 146.96M 147.02M 146.86M 146.81M 146.72M 146.72M 146.18M 145.84M 145.34M 145.52M
Diluted Earnings per Share		 $1.42 $2.04 $1.97 $2.11 $2.34 $2.48 $2.58 $2.37 $2.68 $2.74 $2.64
Weighted Average Diluted Shares Outstanding		 147.55M 147.45M 147.55M 147.60M 147.48M 147.22M 147.34M 146.90M 146.37M 145.72M 146.05M
Weighted Average Basic & Diluted Shares Outstanding		 147.09M 146.91M 146.93M 146.80M 146.87M 146.63M 146.41M 145.97M 145.68M 145.06M 144.25M
Cash Dividends to Common per Share		 $0.48 $0.48 $0.48 $0.53 $0.53 $0.53 $0.53 $0.60 $0.60 $0.60 $0.60

Annual Cash Flow Statements for ResMed

This table details how cash moves in and out of ResMed's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025 6/30/2026
Net Change in Cash & Equivalents		 14 91 -633 -42 316 -168 -22 -46 10 971 260
Net Cash From Operating Activities		 548 414 505 459 802 737 351 693 1,401 1,752 1,806
Net Cash From Continuing Operating Activities		 548 414 505 459 802 737 351 693 1,401 1,752 1,806
Net Income / (Loss) Continuing Operations		 352 342 316 405 622 475 779 898 1,021 1,401 1,523
Consolidated Net Income / (Loss)		 352 342 316 405 622 475 779 898 1,021 1,401 1,523
Depreciation Expense		 87 112 120 151 155 157 160 165 177 198 201
Amortization Expense		 - - 0.00 0.00 27 35 34 32 39 37 43
Non-Cash Adjustments To Reconcile Net Income		 50 39 60 81 97 69 86 60 119 98 113
Changes in Operating Assets and Liabilities, net		 59 -80 9.47 -177 -98 1.41 -708 -462 45 17 -74
Net Cash From Investing Activities		 -1,126 -82 -102 -1,076 -180 -158 -230 -1,160 -270 -200 -545
Net Cash From Continuing Investing Activities		 -1,126 -82 -102 -1,076 -180 -158 -230 -1,160 -270 -200 -545
Purchase of Property, Plant & Equipment		 -59 -62 -63 -69 -95 -103 -135 -120 -99 -90 -156
Acquisitions		 -1,051 -17 -9.78 -960 -39 -53 -64 -1,027 -133 -139 -353
Purchase of Investments		 -8.97 -6.46 -29 -47 -32 -22 -21 -32 -13 -6.42 -29
Sale and/or Maturity of Investments		 -7.10 3.32 - - -14 19 -10 19 -8.70 46 11
Other Investing Activities, net		 - - - - - - - - -15 -11 -19
Net Cash From Financing Activities		 613 -263 -1,027 581 -317 -765 -128 423 -1,119 -606 -1,007
Net Cash From Continuing Financing Activities		 613 -263 -1,027 581 -317 -765 -128 423 -1,119 -606 -1,007
Repayment of Debt		 -284 -545 -1,146 -712 -1,284 -612 -166 -405 -835 -40 -10
Repurchase of Common Equity		 -102 - -54 -23 - - 0.00 0.00 -150 -300 -700
Payment of Dividends		 -169 -198 -200 -213 -225 -230 -245 -261 -284 -312 -350
Issuance of Debt		 1,140 450 350 1,519 1,190 90 288 1,070 105 0.00 0.00
Issuance of Common Equity		 28 38 39 37 48 38 47 49 53 74 75
Other Financing Activities, net		 - -8.16 -15 -28 -46 -50 -52 -31 -8.76 -29 -22
Effect of Exchange Rate Changes		 -21 21 -9.74 -5.56 11 18 -14 -2.15 -1.72 26 6.18
Cash Interest Paid		 11 28 28 36 40 24 22 47 46 28 27
Cash Income Taxes Paid		 69 93 171 243 180 221 478 217 278 214 357

Quarterly Cash Flow Statements for ResMed

This table details how cash moves in and out of ResMed's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 Q4 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 1.15 28 0.45 188 96 411 277 174 33 243 -191
Net Cash From Operating Activities		 273 402 440 326 309 579 539 457 340 554 455
Net Cash From Continuing Operating Activities		 273 402 440 326 309 579 539 457 340 554 455
Net Income / (Loss) Continuing Operations		 209 300 292 311 345 365 380 349 393 399 383
Consolidated Net Income / (Loss)		 209 300 292 311 345 365 380 349 393 399 383
Depreciation Expense		 45 43 44 45 46 44 64 48 50 59 45
Amortization Expense		 8.59 11 11 8.98 9.46 8.24 11 9.97 12 10 10
Non-Cash Adjustments To Reconcile Net Income		 54 6.08 36 20 23 29 26 26 27 35 24
Changes in Operating Assets and Liabilities, net		 -44 41 57 -59 -115 132 59 25 -142 51 -8.37
Net Cash From Investing Activities		 -41 -33 -47 2.15 -37 -32 -134 -53 -51 -58 -384
Net Cash From Continuing Investing Activities		 -41 -33 -47 2.15 -37 -32 -134 -53 -51 -58 -384
Purchase of Property, Plant & Equipment		 -23 -21 -25 -18 -21 -21 -31 -43 -29 -34 -51
Acquisitions		 -8.71 -5.00 -21 -1.77 -3.50 -2.99 -142 -3.34 -6.54 -30 -313
Purchase of Investments		 -3.63 -2.39 -3.07 -1.35 -20 -2.05 -2.01 -2.17 -4.23 -20 -2.00
Sale and/or Maturity of Investments		 -5.46 -4.58 2.58 23 7.42 -5.95 41 -4.10 -12 27 0.92
Net Cash From Financing Activities		 -239 -336 -393 -151 -148 -144 -164 -230 -258 -255 -263
Net Cash From Continuing Financing Activities		 -239 -336 -393 -151 -148 -144 -164 -230 -258 -255 -263
Repayment of Debt		 -130 -220 -300 -30 -5.00 - -5.00 0.00 -5.00 - -5.00
Repurchase of Common Equity		 -50 -50 -50 -50 -75 -75 -100 -150 -175 -175 -200
Payment of Dividends		 -71 -70 -72 -79 -78 -78 -78 -88 -88 -87 -87
Issuance of Common Equity		 20 4.89 28 8.38 27 9.02 30 8.21 30 7.43 29
Other Financing Activities, net		 -7.80 -0.31 0.87 -0.39 -17 -0.36 -11 -0.72 -20 -0.42 -0.39
Effect of Exchange Rate Changes		 8.42 -5.30 0.13 11 -29 7.96 36 -0.07 2.77 2.58 0.91
Cash Interest Paid		 14 11 5.92 7.35 -0.07 14 6.91 6.85 6.61 6.53 7.06
Cash Income Taxes Paid		 97 62 43 106 119 -27 16 62 148 72 76

Annual Balance Sheets for ResMed

This table presents ResMed's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025 6/30/2026
Total Assets		 3,257 3,468 3,064 4,108 4,587 4,728 5,096 6,752 6,872 8,174 8,966
Total Current Assets		 1,420 1,644 1,066 1,145 1,523 1,575 1,931 2,368 2,358 3,506 4,325
Cash & Equivalents		 731 822 189 147 463 295 274 228 238 1,209 1,469
Accounts Receivable		 382 451 484 528 475 614 576 705 837 939 1,036
Inventories, net		 224 268 269 350 417 457 744 998 822 928 946
Prepaid Expenses		 82 103 125 120 75 208 338 437 460 429 416
Other Current Nonoperating Assets		 - - - - - - - - - 0.00 457
Plant, Property, & Equipment, net		 384 394 387 387 417 463 498 538 548 551 582
Total Noncurrent Assets		 1,453 1,430 1,612 2,575 2,647 2,690 2,666 3,846 3,967 4,118 4,059
Goodwill		 1,059 1,065 1,069 1,856 1,890 1,928 1,936 2,770 2,842 3,047 2,910
Intangible Assets		 300 262 215 522 448 393 346 552 486 465 453
Noncurrent Deferred & Refundable Income Taxes		 55 62 54 45 41 80 80 133 204 253 329
Other Noncurrent Operating Assets		 38 42 274 151 267 289 304 390 435 353 368
Total Liabilities & Shareholders' Equity		 3,257 3,468 3,064 4,108 4,587 4,728 5,096 6,752 6,872 8,174 8,966
Total Liabilities		 1,562 1,508 1,005 2,035 2,090 1,842 1,735 2,622 2,008 2,207 2,381
Total Current Liabilities		 638 360 511 556 603 912 689 759 911 1,019 1,395
Short-Term Debt		 299 - 11 12 12 12 9.92 9.90 9.90 9.90 260
Accounts Payable		 93 93 93 116 136 138 159 151 238 278 309
Accrued Expenses		 157 186 186 266 270 321 345 366 378 402 495
Current Deferred Revenue		 50 52 61 89 99 110 109 138 153 166 163
Current Deferred & Payable Income Tax Liabilities		 39 29 160 73 65 308 45 72 108 132 98
Other Current Liabilities		 - - - 0.00 21 24 22 22 25 31 29
Other Current Nonoperating Liabilities		 - - - - - - - - - 0.00 41
Total Noncurrent Liabilities		 924 1,148 494 1,479 1,488 931 1,046 1,863 1,098 1,187 985
Long-Term Debt		 873 1,079 270 1,259 1,164 643 765 1,431 697 658 399
Noncurrent Deferred Revenue		 40 53 210 207 200 154 144 156 137 157 171
Noncurrent Deferred & Payable Income Tax Liabilities		 9.06 14 13 11 13 11 9.71 91 79 78 65
Other Noncurrent Operating Liabilities		 1.21 2.43 0.92 2.06 110 122 126 185 184 295 350
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1,695 1,960 2,059 2,072 2,497 2,886 3,361 4,130 4,864 5,968 6,585
Total Preferred & Common Equity		 1,695 1,960 2,059 2,072 2,497 2,886 3,361 4,130 4,864 5,968 6,585
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 1,695 1,960 2,059 2,072 2,497 2,886 3,361 4,130 4,864 5,968 6,585
Common Stock		 1,304 1,380 1,451 1,512 1,571 1,623 1,683 1,773 1,897 2,034 2,191
Retained Earnings		 2,160 2,316 2,432 2,436 2,833 3,080 3,614 4,253 4,992 6,081 7,255
Treasury Stock		 -1,547 -1,547 -1,600 -1,623 -1,623 -1,623 -1,623 -1,623 -1,773 -2,073 -2,779
Accumulated Other Comprehensive Income / (Loss)		 -223 -189 -224 -253 -284 -193 -313 -273 -252 -75 -83

Quarterly Balance Sheets for ResMed

This table presents ResMed's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 9/30/2025 12/31/2025 3/31/2026
Total Assets		 6,752 6,741 6,905 6,815 6,872 7,222 7,141 7,567 8,308 8,503 8,784
Total Current Assets		 2,368 2,305 2,378 2,351 2,358 2,641 2,836 3,208 3,626 3,819 4,064
Cash & Equivalents		 228 209 210 238 238 426 522 933 1,384 1,417 1,661
Accounts Receivable		 705 692 730 779 837 811 860 908 907 986 999
Inventories, net		 998 958 933 829 822 918 882 863 946 922 912
Prepaid Expenses		 437 445 505 505 460 486 572 505 389 494 493
Plant, Property, & Equipment, net		 538 534 552 540 548 560 520 535 564 564 567
Total Noncurrent Assets		 3,846 3,902 3,975 3,924 3,967 4,021 3,785 3,823 4,119 4,120 4,153
Goodwill		 2,770 2,812 2,862 2,836 2,842 2,886 2,805 2,849 3,044 3,044 3,043
Intangible Assets		 552 563 528 501 486 479 438 430 447 430 425
Noncurrent Deferred & Refundable Income Taxes		 133 138 156 162 204 221 209 217 276 286 313
Other Noncurrent Operating Assets		 390 389 429 424 435 436 332 327 352 360 372
Total Liabilities & Shareholders' Equity		 6,752 6,741 6,905 6,815 6,872 7,222 7,141 7,567 8,308 8,503 8,784
Total Liabilities		 2,622 2,490 2,423 2,185 2,008 2,027 1,888 2,021 2,187 2,182 2,292
Total Current Liabilities		 759 771 764 773 911 904 852 941 1,256 1,248 1,351
Short-Term Debt		 9.90 9.91 9.90 9.90 9.90 9.90 9.91 9.91 260 260 260
Accounts Payable		 151 177 202 177 238 249 220 223 267 250 273
Accrued Expenses		 366 348 332 356 378 366 353 386 396 392 446
Current Deferred Revenue		 138 147 149 151 153 157 157 160 168 176 179
Current Deferred & Payable Income Tax Liabilities		 72 67 47 55 108 94 85 133 135 140 163
Other Current Liabilities		 22 22 24 24 25 28 28 29 30 30 29
Total Noncurrent Liabilities		 1,863 1,720 1,659 1,412 1,098 1,123 1,036 1,080 932 934 941
Long-Term Debt		 1,431 1,352 1,217 997 697 668 663 663 409 404 404
Noncurrent Deferred Revenue		 156 134 140 144 137 144 147 151 159 160 163
Noncurrent Deferred & Payable Income Tax Liabilities		 91 88 89 87 79 84 77 79 78 78 78
Other Noncurrent Operating Liabilities		 185 147 214 184 184 228 150 187 286 293 296
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 4,130 4,250 4,482 4,630 4,864 5,195 5,253 5,546 6,121 6,321 6,492
Total Preferred & Common Equity		 4,130 4,250 4,482 4,630 4,864 5,195 5,253 5,546 6,121 6,321 6,492
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 4,130 4,250 4,482 4,630 4,864 5,195 5,253 5,546 6,121 6,321 6,492
Common Stock		 1,773 1,792 1,824 1,849 1,897 1,925 1,958 1,991 2,063 2,104 2,135
Retained Earnings		 4,253 4,402 4,540 4,770 4,992 5,225 5,492 5,779 6,342 6,647 6,959
Treasury Stock		 -1,623 -1,623 -1,673 -1,723 -1,773 -1,823 -1,898 -1,973 -2,223 -2,400 -2,577
Accumulated Other Comprehensive Income / (Loss)		 -273 -320 -208 -265 -252 -132 -299 -251 -61 -30 -25

Annual Metrics And Ratios for ResMed

This table displays calculated financial ratios and metrics derived from ResMed's official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025 6/30/2026
DEI Shares Outstanding		 - - - - - - - - - - 145,056,384.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 145,056,384.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - 10.50
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 9.52% 12.40% 13.23% 11.38% 13.44% 8.11% 11.93% 18.02% 10.95% 9.84% 9.85%
EBITDA Growth		 6.59% 4.09% 20.51% 10.12% 36.08% 13.40% 6.77% 14.24% 12.90% 24.67% 10.55%
EBIT Growth		 4.43% -0.93% 24.05% 6.61% 40.27% 15.17% 7.92% 16.65% 13.50% 27.24% 11.54%
NOPAT Growth		 3.81% 1.21% -5.76% 37.71% 52.00% -29.33% 67.28% 13.60% 15.53% 32.08% 6.40%
Net Income Growth		 -0.14% -2.87% -7.80% 28.20% 53.65% -23.67% 64.26% 15.15% 13.75% 37.20% 8.75%
EPS Growth		 0.81% -3.61% -8.75% 27.85% 52.50% -24.12% 63.58% 14.91% 13.63% 37.43% 9.67%
Operating Cash Flow Growth		 34.02% -24.43% 21.97% -9.10% 74.76% -8.17% -52.34% 97.44% 102.11% 25.00% 3.10%
Free Cash Flow Firm Growth		 -298.00% 143.00% 47.12% -250.67% 213.51% -33.16% -56.57% -386.21% 292.53% 22.10% 19.13%
Invested Capital Growth		 82.48% 3.78% -2.94% 48.53% 0.44% 1.11% 19.00% 38.34% -0.19% 1.76% -1.24%
Revenue Q/Q Growth		 3.70% 1.88% 2.94% 3.22% 2.26% 3.42% 1.09% 5.16% 2.21% 2.49% 2.09%
EBITDA Q/Q Growth		 6.03% 1.17% 3.54% -2.48% 15.99% 1.74% -0.02% 4.47% 4.68% 5.99% -0.90%
EBIT Q/Q Growth		 4.92% 1.21% 3.65% -4.89% 16.43% 2.09% 0.04% 4.31% 5.53% 5.58% 0.00%
NOPAT Q/Q Growth		 0.25% 6.84% 2.56% -5.51% 16.76% 2.68% 1.51% 2.15% 8.42% 4.84% -0.90%
Net Income Q/Q Growth		 -1.22% 5.71% 2.67% -9.20% 21.27% 3.78% -0.01% 4.01% 6.53% 6.66% 0.25%
EPS Q/Q Growth		 -0.80% 4.80% 2.82% -9.09% 20.96% 3.51% -0.19% 3.92% 6.46% 6.85% 0.58%
Operating Cash Flow Q/Q Growth		 8.43% -1.48% -2.11% 2.78% 30.70% -12.34% -29.51% 29.50% 16.91% 5.97% -4.45%
Free Cash Flow Firm Q/Q Growth		 -848.63% 155.72% 14.60% -5.84% 29.79% -17.27% -22.41% 11.31% 23.04% -9.71% 20.19%
Invested Capital Q/Q Growth		 53.62% 0.95% -0.96% -0.45% -2.15% 1.13% 2.78% 1.00% -1.22% 2.65% -2.48%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 58.00% 58.15% 57.04% 57.32% 58.09% 57.53% 56.57% 55.78% 56.67% 59.36% 61.06%
EBITDA Margin		 28.32% 26.23% 27.91% 27.60% 33.10% 34.72% 33.12% 32.06% 32.62% 37.03% 37.26%
Operating Margin		 23.33% 20.60% 23.15% 22.22% 27.38% 28.27% 27.96% 26.80% 28.17% 32.75% 33.37%
EBIT Margin		 23.60% 20.80% 22.79% 21.81% 26.97% 28.73% 27.70% 27.38% 28.01% 32.45% 32.95%
Profit (Net Income) Margin		 19.17% 16.56% 13.49% 15.52% 21.02% 14.84% 21.78% 21.25% 21.79% 27.22% 26.94%
Tax Burden Percent		 80.17% 81.74% 60.54% 77.98% 84.80% 53.70% 81.15% 81.47% 80.72% 83.50% 79.36%
Interest Burden Percent		 101.30% 97.41% 97.75% 91.26% 91.92% 96.21% 96.89% 95.27% 96.38% 100.46% 103.05%
Effective Tax Rate		 19.83% 18.26% 39.46% 22.02% 15.20% 46.30% 18.85% 18.53% 19.28% 16.50% 20.64%
Return on Invested Capital (ROIC)		 20.80% 15.99% 15.02% 16.89% 21.44% 15.03% 22.84% 20.04% 19.96% 26.16% 27.76%
ROIC Less NNEP Spread (ROIC-NNEP)		 89.76% 14.34% 7.91% 9.15% 14.37% 13.03% 15.34% 17.16% 14.67% 44.17% 24.83%
Return on Net Nonoperating Assets (RNNOA)		 0.67% 2.74% 0.69% 2.69% 5.77% 2.60% 2.12% 3.93% 2.74% -0.29% -3.50%
Return on Equity (ROE)		 21.47% 18.73% 15.70% 19.59% 27.21% 17.63% 24.96% 23.96% 22.70% 25.86% 24.27%
Cash Return on Invested Capital (CROIC)		 -37.60% 12.28% 18.00% -22.16% 21.00% 13.93% 5.49% -12.14% 20.15% 24.41% 29.01%
Operating Return on Assets (OROA)		 15.96% 12.78% 16.33% 15.86% 18.34% 19.72% 20.18% 19.52% 19.27% 22.19% 21.73%
Return on Assets (ROA)		 12.96% 10.18% 9.66% 11.28% 14.30% 10.19% 15.87% 15.15% 14.99% 18.62% 17.77%
Return on Common Equity (ROCE)		 21.47% 18.73% 15.70% 19.59% 27.21% 17.63% 24.96% 23.96% 22.70% 25.86% 24.27%
Return on Equity Simple (ROE_SIMPLE)		 20.79% 17.46% 15.33% 19.52% 24.90% 16.44% 23.19% 21.73% 20.99% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 344 348 328 452 687 485 812 922 1,065 1,407 1,497
NOPAT Margin		 18.70% 16.84% 14.02% 17.33% 23.22% 15.18% 22.69% 21.84% 22.74% 27.34% 26.49%
Net Nonoperating Expense Percent (NNEP)		 -68.96% 1.65% 7.11% 7.75% 7.07% 2.00% 7.50% 2.87% 5.29% -18.01% 2.94%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - - 21.21% 20.67%
Cost of Revenue to Revenue		 42.00% 41.85% 42.96% 42.68% 41.91% 42.47% 43.43% 44.22% 43.33% 40.64% 38.94%
SG&A Expenses to Revenue		 26.54% 26.80% 25.65% 24.75% 22.88% 20.97% 20.61% 20.70% 19.57% 19.26% 19.80%
R&D to Revenue		 6.45% 6.99% 6.63% 6.93% 6.83% 7.05% 7.09% 6.81% 6.56% 6.44% 6.69%
Operating Expenses to Revenue		 34.67% 37.54% 33.89% 35.10% 30.71% 29.26% 28.62% 28.98% 28.50% 26.61% 27.68%
Earnings before Interest and Taxes (EBIT)		 434 430 533 569 798 918 991 1,156 1,312 1,670 1,863
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 521 542 653 719 979 1,110 1,185 1,354 1,529 1,906 2,107
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 4.76 5.22 6.76 8.07 10.73 12.09 8.94 7.67 5.77 6.34 4.29
Price to Tangible Book Value (P/TBV)		 24.01 16.15 17.97 0.00 169.08 61.73 27.85 39.26 18.26 15.40 8.77
Price to Revenue (P/Rev)		 4.39 4.95 5.95 6.41 9.06 10.91 8.39 7.50 5.99 7.35 5.00
Price to Earnings (P/E)		 22.88 29.90 44.12 41.31 43.12 73.53 38.54 35.31 27.48 27.01 18.56
Dividend Yield		 2.09% 2.25% 1.44% 1.27% 0.84% 0.65% 0.82% 0.82% 1.01% 0.82% 1.23%
Earnings Yield		 4.37% 3.34% 2.27% 2.42% 2.32% 1.36% 2.60% 2.83% 3.64% 3.70% 5.39%
Enterprise Value to Invested Capital (EV/IC)		 3.98 4.73 6.51 5.58 8.57 10.86 7.91 6.16 5.35 6.87 5.12
Enterprise Value to Revenue (EV/Rev)		 4.63 5.08 5.99 6.84 9.31 11.03 8.53 7.79 6.09 7.25 4.86
Enterprise Value to EBITDA (EV/EBITDA)		 16.33 19.35 21.46 24.80 28.11 31.76 25.77 24.30 18.66 19.57 13.03
Enterprise Value to EBIT (EV/EBIT)		 19.60 24.40 26.29 31.38 34.51 38.38 30.81 28.46 21.73 22.33 14.74
Enterprise Value to NOPAT (EV/NOPAT)		 24.73 30.14 42.74 39.49 40.08 72.65 37.62 35.68 26.77 26.50 18.34
Enterprise Value to Operating Cash Flow (EV/OCF)		 15.52 25.33 27.76 38.86 34.30 47.85 86.97 47.46 20.36 21.29 15.21
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 39.25 35.65 0.00 40.92 78.43 156.44 0.00 26.52 28.39 17.55
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.69 0.55 0.14 0.61 0.47 0.23 0.23 0.35 0.15 0.11 0.10
Long-Term Debt to Equity		 0.52 0.55 0.13 0.61 0.47 0.22 0.23 0.35 0.14 0.11 0.06
Financial Leverage		 0.01 0.19 0.09 0.29 0.40 0.20 0.14 0.23 0.19 -0.01 -0.14
Leverage Ratio		 1.66 1.84 1.63 1.74 1.90 1.73 1.57 1.58 1.51 1.39 1.37
Compound Leverage Factor		 1.68 1.79 1.59 1.58 1.75 1.67 1.52 1.51 1.46 1.40 1.41
Debt to Total Capital		 40.90% 35.49% 12.03% 38.01% 32.02% 18.51% 18.74% 25.87% 12.69% 10.07% 9.10%
Short-Term Debt to Total Capital		 10.44% 0.00% 0.49% 0.36% 0.33% 0.34% 0.24% 0.18% 0.18% 0.15% 3.59%
Long-Term Debt to Total Capital		 30.46% 35.49% 11.54% 37.66% 31.69% 18.17% 18.50% 25.69% 12.52% 9.92% 5.51%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 59.10% 64.51% 87.97% 61.99% 67.98% 81.49% 81.26% 74.13% 87.31% 89.93% 90.90%
Debt to EBITDA		 2.25 1.99 0.43 1.77 1.20 0.59 0.65 1.06 0.46 0.35 0.31
Net Debt to EBITDA		 0.85 0.47 0.14 1.56 0.73 0.32 0.42 0.90 0.31 -0.28 -0.38
Long-Term Debt to EBITDA		 1.68 1.99 0.41 1.75 1.19 0.58 0.65 1.06 0.46 0.35 0.19
Debt to NOPAT		 3.41 3.10 0.86 2.81 1.71 1.35 0.96 1.56 0.66 0.47 0.44
Net Debt to NOPAT		 1.28 0.74 0.28 2.49 1.04 0.74 0.62 1.32 0.44 -0.38 -0.54
Long-Term Debt to NOPAT		 2.54 3.10 0.82 2.79 1.70 1.33 0.94 1.55 0.65 0.47 0.27
Altman Z-Score		 5.32 6.45 10.98 7.02 10.02 13.76 13.02 9.61 10.96 13.00 9.97
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.23 4.57 2.08 2.06 2.53 1.73 2.80 3.12 2.59 3.44 3.10
Quick Ratio		 1.75 3.53 1.32 1.22 1.56 1.00 1.23 1.23 1.18 2.11 1.80
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -622 267 393 -592 673 449 195 -559 1,076 1,313 1,565
Operating Cash Flow to CapEx		 936.09% 665.48% 807.00% 668.10% 841.56% 717.27% 260.43% 579.33% 1,408.87% 1,949.13% 1,155.47%
Free Cash Flow to Firm to Interest Expense		 -55.47 9.47 13.87 -16.39 17.09 19.02 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 48.90 14.66 17.81 12.70 20.38 31.18 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 43.67 12.46 15.60 10.80 17.96 26.83 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.68 0.61 0.72 0.73 0.68 0.69 0.73 0.71 0.69 0.68 0.66
Accounts Receivable Turnover		 4.94 4.96 5.01 5.15 5.90 5.87 6.01 6.59 6.08 5.79 5.72
Inventory Turnover		 3.28 3.51 3.74 3.60 3.23 3.11 2.59 2.14 2.23 2.39 2.35
Fixed Asset Turnover		 4.76 5.31 5.99 6.74 7.35 7.26 7.44 8.15 8.63 9.37 9.98
Accounts Payable Turnover		 8.89 9.33 10.84 10.67 9.85 9.92 10.45 12.05 10.45 8.11 7.50
Days Sales Outstanding (DSO)		 73.91 73.52 72.85 70.87 61.91 62.17 60.71 55.35 60.07 63.01 63.78
Days Inventory Outstanding (DIO)		 111.39 103.97 97.49 101.44 112.89 117.47 141.05 170.24 163.64 152.71 155.30
Days Payable Outstanding (DPO)		 41.05 39.10 33.67 34.19 37.04 36.80 34.91 30.30 34.93 45.02 48.66
Cash Conversion Cycle (CCC)		 144.25 138.39 136.67 138.11 137.76 142.84 166.85 195.30 188.79 170.70 170.41
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 2,136 2,217 2,152 3,196 3,210 3,246 3,862 5,343 5,333 5,427 5,359
Invested Capital Turnover		 1.11 0.95 1.07 0.97 0.92 0.99 1.01 0.92 0.88 0.96 1.05
Increase / (Decrease) in Invested Capital		 966 81 -65 1,044 14 36 617 1,481 -10 94 -67
Enterprise Value (EV)		 8,505 10,490 14,018 17,839 27,518 35,252 30,537 32,904 28,523 37,289 27,459
Market Capitalization		 8,063 10,233 13,925 16,715 26,805 34,892 30,036 31,691 28,054 37,830 28,269
Book Value per Share		 $12.07 $13.82 $14.42 $14.45 $17.26 $19.83 $22.97 $28.11 $33.11 $40.70 $45.40
Tangible Book Value per Share		 $2.39 $4.47 $5.43 ($2.14) $1.10 $3.88 $7.37 $5.49 $10.46 $16.75 $22.22
Total Capital		 2,868 3,039 2,340 3,343 3,673 3,541 4,136 5,571 5,571 6,636 7,245
Total Debt		 1,173 1,079 281 1,271 1,176 655 775 1,441 707 668 659
Total Long-Term Debt		 873 1,079 270 1,259 1,164 643 765 1,431 697 658 399
Net Debt		 441 257 93 1,124 713 360 502 1,213 469 -541 -810
Capital Expenditures (CapEx)		 59 62 63 69 95 103 135 120 99 90 156
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 350 462 377 454 470 380 978 1,391 1,219 1,287 1,720
Debt-free Net Working Capital (DFNWC)		 1,081 1,284 566 601 933 675 1,252 1,619 1,457 2,496 3,190
Net Working Capital (NWC)		 782 1,284 554 589 921 663 1,242 1,609 1,447 2,486 2,930
Net Nonoperating Expense (NNE)		 -8.51 5.77 12 47 65 11 32 25 44 6.51 -26
Net Nonoperating Obligations (NNO)		 441 257 93 1,124 713 360 502 1,213 469 -541 -1,226
Total Depreciation and Amortization (D&A)		 87 112 120 151 181 192 194 198 216 236 244
Debt-free, Cash-free Net Working Capital to Revenue		 19.02% 22.35% 16.12% 17.43% 15.88% 11.88% 27.34% 32.95% 26.01% 25.01% 30.43%
Debt-free Net Working Capital to Revenue		 58.80% 62.12% 24.18% 23.07% 31.54% 21.11% 34.99% 38.34% 31.10% 48.51% 56.42%
Net Working Capital to Revenue		 42.52% 62.12% 23.69% 22.61% 31.14% 20.74% 34.72% 38.11% 30.89% 48.32% 51.82%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $2.51 $2.42 $2.21 $2.83 $4.31 $3.27 $5.34 $6.12 $6.94 $9.55 $10.47
Adjusted Weighted Average Basic Shares Outstanding		 140.24M 141.36M 142.76M 143.11M 144.34M 145.31M 146.07M 146.77M 147.02M 146.72M 145.52M
Adjusted Diluted Earnings per Share		 $2.49 $2.40 $2.19 $2.80 $4.27 $3.24 $5.30 $6.09 $6.92 $9.51 $10.43
Adjusted Weighted Average Diluted Shares Outstanding		 141.67M 142.45M 143.99M 144.48M 145.65M 146.45M 147.04M 147.46M 147.55M 147.34M 146.05M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 140.70M 142.21M 142.68M 143.67M 144.90M 145.68K 146.42M 147.07M 146.93M 146.41M 144.25M
Normalized Net Operating Profit after Tax (NOPAT)		 349 373 339 491 686 490 813 939 1,117 1,407 1,515
Normalized NOPAT Margin		 19.00% 18.06% 14.49% 18.84% 23.20% 15.32% 22.73% 22.23% 23.85% 27.34% 26.79%
Pre Tax Income Margin		 23.91% 20.26% 22.28% 19.91% 24.79% 27.64% 26.84% 26.09% 27.00% 32.60% 33.95%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 38.72 15.23 18.81 15.72 20.26 38.87 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 30.69 12.33 11.57 12.49 17.45 20.54 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 33.50 13.02 16.60 13.82 17.84 34.53 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 25.47 10.12 9.36 10.59 15.02 16.19 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 48.06% 57.85% 63.37% 52.55% 36.26% 48.52% 31.48% 29.04% 27.78% 22.26% 22.95%
Augmented Payout Ratio		 77.02% 57.85% 80.42% 58.20% 36.26% 48.52% 31.48% 29.04% 42.47% 43.67% 68.91%

Quarterly Metrics And Ratios for ResMed

This table displays calculated financial ratios and metrics derived from ResMed's official financial filings.

Metric Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 Q4 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - - - - - 145,678,401.00 145,056,384.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - 145,678,401.00 145,056,384.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - 2.74 2.64
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 12.48% 7.17% 9.01% 11.08% 10.26% 7.92% 10.20% 9.07% 10.98% 10.81% 8.58%
EBITDA Growth		 -1.96% 23.32% 19.58% 27.12% 45.42% 6.32% 25.81% 12.85% 15.84% 18.97% -3.65%
EBIT Growth		 -5.00% 26.76% 23.41% 32.01% 53.39% 7.92% 24.32% 13.62% 16.43% 17.22% 0.00%
NOPAT Growth		 -3.85% 24.11% 36.36% 34.98% 55.26% 24.25% 20.99% 10.78% 13.18% 6.50% -3.70%
Net Income Growth		 -7.16% 29.24% 27.25% 41.90% 65.05% 21.48% 29.93% 11.94% 13.92% 9.23% 0.98%
EPS Growth		 -7.19% 29.11% 27.10% 41.61% 64.79% 21.57% 30.96% 12.32% 14.53% 10.48% 2.33%
Operating Cash Flow Growth		 112.10% 42.28% 85.36% 13.71% 13.12% 43.93% 22.42% 40.48% 10.08% -4.24% -15.62%
Free Cash Flow Firm Growth		 100.61% 114.82% 125.68% 123.59% 4,977.63% 153.50% -12.03% 43.35% -48.60% -61.30% 52.04%
Invested Capital Growth		 4.03% 2.05% -0.19% 0.80% -1.72% -2.08% 1.76% -0.74% 3.03% 3.95% -1.24%
Revenue Q/Q Growth		 5.49% 2.94% 2.19% 0.11% 4.70% 0.75% 4.36% -0.92% 6.53% 0.60% 2.25%
EBITDA Q/Q Growth		 -5.40% 35.21% -5.24% 4.88% 8.22% -1.15% 12.13% -5.93% 11.10% 1.52% -9.18%
EBIT Q/Q Growth		 -6.36% 41.64% -6.02% 5.90% 8.80% -0.35% 8.27% -3.22% 11.49% 0.33% -7.63%
NOPAT Q/Q Growth		 -4.97% 35.43% 3.87% 0.97% 9.31% 8.38% 1.14% -7.55% 11.69% 1.98% -8.54%
Net Income Q/Q Growth		 -4.84% 43.91% -2.75% 6.54% 10.68% 5.93% 4.02% -8.21% 12.64% 1.56% -3.84%
EPS Q/Q Growth		 -4.70% 43.66% -3.43% 7.11% 10.90% 5.98% 4.03% -8.14% 13.08% 2.24% -3.65%
Operating Cash Flow Q/Q Growth		 -4.70% 47.35% 9.47% -26.03% -5.20% 87.50% -6.89% -15.12% -25.71% 63.10% -17.96%
Free Cash Flow Firm Q/Q Growth		 100.75% 2,117.28% 68.12% -15.75% 61.69% 10.70% -41.66% 37.29% -42.02% -16.66% 129.22%
Invested Capital Q/Q Growth		 1.77% -1.81% -1.22% 2.12% -0.78% -2.17% 2.65% -0.38% 2.99% -1.30% -2.48%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 55.64% 57.88% 58.50% 58.57% 58.60% 59.33% 60.84% 61.46% 61.76% 62.25% 58.84%
EBITDA Margin		 28.03% 36.81% 34.14% 35.76% 36.96% 36.27% 38.97% 37.00% 38.59% 38.94% 34.58%
Operating Margin		 23.66% 31.29% 31.17% 31.63% 32.54% 33.00% 33.72% 33.43% 34.56% 34.92% 30.66%
EBIT Margin		 23.44% 32.25% 29.66% 31.38% 32.60% 32.25% 33.46% 32.68% 34.21% 34.11% 30.82%
Profit (Net Income) Margin		 17.96% 25.10% 23.89% 25.43% 26.88% 28.26% 28.17% 26.10% 27.59% 27.86% 26.20%
Tax Burden Percent		 80.48% 80.04% 81.69% 81.19% 82.38% 87.39% 82.90% 78.01% 79.13% 79.38% 80.87%
Interest Burden Percent		 95.21% 97.26% 98.61% 99.82% 100.07% 100.27% 101.56% 102.36% 101.94% 102.87% 105.13%
Effective Tax Rate		 19.52% 19.96% 18.31% 18.81% 17.62% 12.61% 17.10% 21.99% 20.87% 20.62% 19.14%
Return on Invested Capital (ROIC)		 15.90% 21.48% 22.35% 22.76% 24.23% 27.11% 26.74% 25.27% 26.91% 28.47% 25.99%
ROIC Less NNEP Spread (ROIC-NNEP)		 14.92% 21.55% 20.07% 22.32% 24.38% 24.16% 18.68% 25.18% 25.73% 28.16% 23.66%
Return on Net Nonoperating Assets (RNNOA)		 4.65% 5.35% 3.75% 3.32% 2.92% 1.21% -0.12% -1.03% -1.34% -2.94% -3.33%
Return on Equity (ROE)		 20.56% 26.84% 26.10% 26.08% 27.16% 28.32% 26.61% 24.24% 25.57% 25.53% 22.66%
Cash Return on Invested Capital (CROIC)		 13.20% 16.36% 20.15% 20.34% 25.02% 27.23% 24.41% 27.30% 24.10% 24.15% 29.01%
Operating Return on Assets (OROA)		 15.55% 21.86% 20.40% 21.60% 22.87% 22.52% 22.89% 22.13% 23.61% 23.11% 20.33%
Return on Assets (ROA)		 11.91% 17.01% 16.43% 17.51% 18.86% 19.73% 19.27% 17.67% 19.04% 18.87% 17.28%
Return on Common Equity (ROCE)		 20.56% 26.84% 26.10% 26.08% 27.16% 28.32% 26.61% 24.24% 25.57% 25.53% 22.66%
Return on Equity Simple (ROE_SIMPLE)		 19.87% 20.70% 0.00% 21.42% 23.77% 23.68% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 221 300 311 314 344 373 377 348 389 397 363
NOPAT Margin		 19.04% 25.05% 25.46% 25.68% 26.81% 28.84% 27.95% 26.08% 27.34% 27.72% 24.79%
Net Nonoperating Expense Percent (NNEP)		 0.98% -0.06% 2.28% 0.44% -0.15% 2.94% 8.06% 0.09% 1.18% 0.32% 2.33%
Return On Investment Capital (ROIC_SIMPLE)		 3.88% - - - 5.80% 5.99% 5.68% 5.13% 5.57% 5.54% 5.01%
Cost of Revenue to Revenue		 44.36% 42.12% 41.50% 41.43% 41.40% 40.67% 39.16% 38.54% 38.24% 37.76% 41.16%
SG&A Expenses to Revenue		 19.11% 19.21% 19.80% 19.52% 18.85% 18.99% 19.67% 19.41% 19.57% 19.96% 20.24%
R&D to Revenue		 6.35% 6.44% 6.61% 6.49% 6.35% 6.50% 6.41% 6.54% 6.39% 6.59% 7.22%
Operating Expenses to Revenue		 31.98% 26.58% 27.33% 26.94% 26.05% 26.33% 27.12% 28.02% 27.20% 27.33% 28.18%
Earnings before Interest and Taxes (EBIT)		 273 386 363 384 418 417 451 437 487 488 451
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 326 441 418 438 474 468 525 494 549 557 506
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 5.59 6.26 5.77 6.90 6.39 5.93 6.34 6.55 5.56 5.04 4.29
Price to Tangible Book Value (P/TBV)		 22.96 22.43 18.26 19.60 16.70 14.50 15.40 15.24 12.35 10.82 8.77
Price to Revenue (P/Rev)		 5.57 6.32 5.99 7.46 6.81 6.55 7.35 7.62 6.51 5.91 5.00
Price to Earnings (P/E)		 28.15 30.25 27.48 32.23 26.88 25.03 27.01 27.87 23.66 21.52 18.56
Dividend Yield		 1.08% 0.95% 1.01% 0.81% 0.88% 0.92% 0.82% 0.80% 0.94% 1.04% 1.23%
Earnings Yield		 3.55% 3.31% 3.64% 3.10% 3.72% 3.99% 3.70% 3.59% 4.23% 4.65% 5.39%
Enterprise Value to Invested Capital (EV/IC)		 4.74 5.51 5.35 6.63 6.24 6.17 6.87 7.28 6.18 5.77 5.12
Enterprise Value to Revenue (EV/Rev)		 5.79 6.49 6.09 7.51 6.84 6.50 7.25 7.49 6.37 5.73 4.86
Enterprise Value to EBITDA (EV/EBITDA)		 18.95 20.38 18.66 22.27 19.05 18.14 19.57 20.06 16.89 14.91 13.03
Enterprise Value to EBIT (EV/EBIT)		 22.45 23.93 21.73 25.70 21.74 20.62 22.33 22.86 19.21 17.02 14.74
Enterprise Value to NOPAT (EV/NOPAT)		 28.21 30.29 26.77 31.49 26.57 24.30 26.50 27.32 23.15 20.98 18.34
Enterprise Value to Operating Cash Flow (EV/OCF)		 24.17 24.83 20.36 25.07 22.84 19.73 21.29 20.90 17.97 16.78 15.21
Enterprise Value to Free Cash Flow (EV/FCFF)		 36.64 34.04 26.52 32.73 24.73 22.42 28.39 26.58 26.02 24.35 17.55
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.27 0.22 0.15 0.13 0.13 0.12 0.11 0.11 0.11 0.10 0.10
Long-Term Debt to Equity		 0.27 0.22 0.14 0.13 0.13 0.12 0.11 0.07 0.06 0.06 0.06
Financial Leverage		 0.31 0.25 0.19 0.15 0.12 0.05 -0.01 -0.04 -0.05 -0.10 -0.14
Leverage Ratio		 1.65 1.58 1.51 1.48 1.44 1.41 1.39 1.37 1.35 1.36 1.37
Compound Leverage Factor		 1.57 1.54 1.49 1.48 1.44 1.42 1.41 1.40 1.38 1.40 1.44
Debt to Total Capital		 21.49% 17.86% 12.69% 11.54% 11.35% 10.82% 10.07% 9.85% 9.50% 9.28% 9.10%
Short-Term Debt to Total Capital		 0.17% 0.18% 0.18% 0.17% 0.17% 0.16% 0.15% 3.83% 3.72% 3.63% 3.59%
Long-Term Debt to Total Capital		 21.32% 17.69% 12.52% 11.37% 11.19% 10.66% 9.92% 6.02% 5.78% 5.65% 5.51%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 78.51% 82.14% 87.31% 88.46% 88.65% 89.18% 89.93% 90.15% 90.50% 90.72% 90.90%
Debt to EBITDA		 0.89 0.69 0.46 0.42 0.38 0.37 0.35 0.34 0.33 0.31 0.31
Net Debt to EBITDA		 0.74 0.53 0.31 0.15 0.09 -0.14 -0.28 -0.36 -0.37 -0.47 -0.38
Long-Term Debt to EBITDA		 0.88 0.68 0.46 0.41 0.37 0.37 0.35 0.21 0.20 0.19 0.19
Debt to NOPAT		 1.33 1.02 0.66 0.59 0.53 0.50 0.47 0.46 0.45 0.44 0.44
Net Debt to NOPAT		 1.10 0.78 0.44 0.22 0.12 -0.19 -0.38 -0.50 -0.51 -0.66 -0.54
Long-Term Debt to NOPAT		 1.32 1.01 0.65 0.58 0.52 0.49 0.47 0.28 0.27 0.27 0.27
Altman Z-Score		 8.19 10.08 10.51 12.76 12.96 12.04 12.50 13.21 11.95 10.85 9.45
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.11 3.04 2.59 2.92 3.33 3.41 3.44 2.89 3.06 3.01 3.10
Quick Ratio		 1.23 1.32 1.18 1.37 1.62 1.96 2.11 1.82 1.93 1.97 1.80
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 8.63 191 322 271 438 485 283 388 225 188 430
Operating Cash Flow to CapEx		 1,168.30% 1,897.18% 1,768.88% 1,824.76% 1,494.98% 2,782.56% 1,761.54% 1,064.40% 1,190.46% 1,646.56% 889.22%
Free Cash Flow to Firm to Interest Expense		 0.00 17.35 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 36.46 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 34.54 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.66 0.68 0.69 0.69 0.70 0.70 0.68 0.68 0.69 0.68 0.66
Accounts Receivable Turnover		 6.43 6.26 6.08 6.39 6.20 5.95 5.79 6.12 5.85 5.81 5.72
Inventory Turnover		 2.10 2.20 2.23 2.17 2.26 2.45 2.39 2.25 2.34 2.40 2.35
Fixed Asset Turnover		 8.38 8.58 8.63 8.79 9.19 9.34 9.37 9.36 9.96 10.05 9.98
Accounts Payable Turnover		 10.15 11.95 10.45 9.55 9.70 10.36 8.11 8.13 8.97 8.58 7.50
Days Sales Outstanding (DSO)		 56.81 58.34 60.07 57.08 58.89 61.31 63.01 59.65 62.40 62.83 63.78
Days Inventory Outstanding (DIO)		 173.49 165.73 163.64 168.26 161.61 149.10 152.71 162.06 155.89 152.24 155.30
Days Payable Outstanding (DPO)		 35.96 30.55 34.93 38.23 37.63 35.25 45.02 44.87 40.67 42.54 48.66
Cash Conversion Cycle (CCC)		 194.34 193.52 188.79 187.10 182.86 175.17 170.70 176.84 177.61 172.54 170.41
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 5,498 5,399 5,333 5,446 5,404 5,286 5,427 5,406 5,568 5,495 5,359
Invested Capital Turnover		 0.84 0.86 0.88 0.89 0.90 0.94 0.96 0.97 0.98 1.03 1.05
Increase / (Decrease) in Invested Capital		 213 108 -10 43 -94 -113 94 -40 164 209 -67
Enterprise Value (EV)		 26,085 29,763 28,523 36,120 33,722 32,616 37,289 39,363 34,406 31,705 27,459
Market Capitalization		 25,069 28,994 28,054 35,869 33,571 32,876 37,830 40,078 35,159 32,702 28,269
Book Value per Share		 $30.47 $31.48 $33.11 $35.36 $35.78 $37.76 $40.70 $41.81 $43.30 $44.56 $45.40
Tangible Book Value per Share		 $7.42 $8.79 $10.46 $12.46 $13.69 $15.44 $16.75 $17.96 $19.50 $20.76 $22.22
Total Capital		 5,709 5,637 5,571 5,873 5,926 6,219 6,636 6,790 6,985 7,156 7,245
Total Debt		 1,227 1,007 707 677 673 673 668 669 664 664 659
Total Long-Term Debt		 1,217 997 697 668 663 663 658 409 404 404 399
Net Debt		 1,016 769 469 251 151 -260 -541 -715 -753 -996 -810
Capital Expenditures (CapEx)		 23 21 25 18 21 21 31 43 29 34 51
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 1,414 1,350 1,219 1,321 1,472 1,345 1,287 1,246 1,414 1,312 1,720
Debt-free Net Working Capital (DFNWC)		 1,624 1,588 1,457 1,747 1,994 2,278 2,496 2,630 2,831 2,973 3,190
Net Working Capital (NWC)		 1,614 1,578 1,447 1,737 1,984 2,268 2,486 2,370 2,571 2,713 2,930
Net Nonoperating Expense (NNE)		 13 -0.67 19 3.10 -0.89 7.49 -2.91 -0.20 -3.55 -1.99 -21
Net Nonoperating Obligations (NNO)		 1,016 769 469 251 151 -260 -541 -715 -753 -996 -1,226
Total Depreciation and Amortization (D&A)		 53 55 55 54 56 52 74 58 62 69 55
Debt-free, Cash-free Net Working Capital to Revenue		 31.39% 29.45% 26.01% 27.47% 29.88% 26.79% 25.01% 23.71% 26.19% 23.70% 30.43%
Debt-free Net Working Capital to Revenue		 36.05% 34.64% 31.10% 36.34% 40.48% 45.36% 48.51% 50.03% 52.44% 53.68% 56.42%
Net Working Capital to Revenue		 35.83% 34.43% 30.89% 36.13% 40.27% 45.16% 48.32% 45.08% 47.62% 48.99% 51.82%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $1.42 $2.04 $1.99 $2.12 $2.35 $2.49 $2.59 $2.38 $2.69 $2.74 $2.66
Adjusted Weighted Average Basic Shares Outstanding		 147.13M 146.96M 147.02M 146.86M 146.81M 146.72M 146.72M 146.18M 145.84M 145.34M 145.52M
Adjusted Diluted Earnings per Share		 $1.42 $2.04 $1.97 $2.11 $2.34 $2.48 $2.58 $2.37 $2.68 $2.74 $2.64
Adjusted Weighted Average Diluted Shares Outstanding		 147.55M 147.45M 147.55M 147.60M 147.48M 147.22M 147.34M 146.90M 146.37M 145.72M 146.05M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 147.09M 146.91M 146.93M 146.80M 146.87M 146.63M 146.41M 145.97M 145.68M 145.06M 144.25M
Normalized Net Operating Profit after Tax (NOPAT)		 273 300 311 314 344 373 377 361 394 397 363
Normalized NOPAT Margin		 23.48% 25.05% 25.46% 25.68% 26.81% 28.84% 27.95% 27.00% 27.67% 27.72% 24.79%
Pre Tax Income Margin		 22.31% 31.36% 29.25% 31.32% 32.63% 32.34% 33.98% 33.45% 34.87% 35.09% 32.40%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 35.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 27.19 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 33.09 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 25.27 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 30.80% 29.09% 27.78% 26.10% 23.82% 23.20% 22.26% 22.31% 22.25% 22.39% 22.95%
Augmented Payout Ratio		 36.42% 39.53% 42.47% 44.07% 41.84% 42.24% 43.67% 50.13% 55.91% 61.87% 68.91%

Financials Breakdown Chart

Key Financial Trends

ResMed’s financial statements show a business that has expanded substantially over the past several years. Quarterly revenue increased from $864.5 million in Q3 2022 to $1.46 billion in Q4 2026, while net income rose from $179.0 million to $383.4 million over the same period. The latest quarter, however, showed some sequential margin pressure and weaker operating cash flow.

  • Strong long-term revenue growth: Q4 2026 revenue of $1.46 billion was up 8.6% from $1.35 billion in Q4 2025 and roughly 60% above Q3 2022.
  • Net income and EPS have generally trended higher: Q4 2026 net income was $383.4 million, compared with $379.7 million in Q4 2025 and $195.1 million in Q4 2022. Diluted EPS increased to $2.64 from $2.58 year over year.
  • Resilient profitability: Despite higher costs, Q4 2026 produced a 58.8% gross margin, a 30.7% operating margin and a 26.2% net margin. Operating income increased from $275.3 million in Q4 2022 to $448.7 million in Q4 2026.
  • Healthy balance-sheet liquidity: Cash and equivalents reached $1.66 billion in the latest reported balance sheet, up from $932.7 million in Q3 2025 and $238.4 million at Q4 2024.
  • Debt reduction has improved financial flexibility: Total debt declined to approximately $664 million in Q3 2026 from about $1.66 billion in Q3 2025 and $1.44 billion at Q4 2024.
  • Shareholder returns remain significant: The quarterly dividend increased from $0.42 in 2022 to $0.60 in 2026. ResMed also repurchased $200 million of stock in Q4 2026, supporting per-share earnings and reducing the share count over time.
  • Acquisition spending is becoming more material: ResMed spent $312.8 million on acquisitions in Q4 2026, compared with $141.8 million in Q4 2025. These investments could support future growth, but investors should monitor whether acquired assets generate adequate returns.
  • Goodwill remains elevated: Goodwill was approximately $3.04 billion in Q3 2026, representing a significant portion of total assets. This increases the importance of successful integration and leaves the company exposed to potential impairment charges if acquired businesses underperform.
  • Latest-quarter margins weakened sequentially: Compared with Q3 2026, Q4 revenue increased 2.3%, but gross profit fell 3.3% and operating income declined 10.2%. The gross margin fell from approximately 62.2% to 58.8%, suggesting higher product or operating costs.
  • Operating cash flow slowed: Q4 2026 operating cash flow was $454.6 million, down from $554.1 million in Q3 2026 and $538.8 million in Q4 2025. Working-capital changes were a use of $8.4 million in Q4, compared with a $51.2 million benefit in Q3.

ResMed’s cash generation remains strong enough to fund dividends, buybacks, acquisitions and capital expenditures. In Q4 2026, operating cash flow of $454.6 million exceeded capital expenditures of $51.1 million, although the company’s $312.8 million acquisition outlay and $200 million stock repurchase contributed to a $191.3 million decline in cash during the quarter.

The balance sheet is materially stronger than it was earlier in the period. Total liabilities were $2.29 billion in Q3 2026 against $6.49 billion of equity, while the current ratio was approximately 3.0 based on reported current assets and current liabilities. This provides a meaningful cushion, although the company continues to carry substantial goodwill and intangible assets from prior acquisitions.

Overall, the statements point to a company with durable revenue growth, high margins, strong liquidity and an active capital-return program. The main issues for investors to watch are the recent contraction in gross and operating margins, the decline in quarterly operating cash flow, and whether increased acquisition spending can produce sustainable earnings growth. Some historical figures in the supplied dataset are marked as restated or calculated, so comparisons should be confirmed against ResMed’s latest filings.

09/01/26 01:48 AM ETAI Generated. May Contain Errors.

ResMed Financials - Frequently Asked Questions

According to the most recent income statement we have on file, ResMed's fiscal year ends in June. Their fiscal year 2026 ended on June 30, 2026.

ResMed's net income appears to be on an upward trend, with a most recent value of $1.52 billion in 2026, rising from $352.41 million in 2016. The previous period was $1.40 billion in 2025. Check out ResMed's forecast to explore projected trends and price targets.

ResMed's total operating income in 2026 was $1.89 billion, based on the following breakdown:
  • Total Gross Profit: $3.45 billion
  • Total Operating Expenses: $1.57 billion

Over the last 10 years, ResMed's total revenue changed from $1.84 billion in 2016 to $5.65 billion in 2026, a change of 207.5%.

ResMed's total liabilities were at $2.38 billion at the end of 2026, a 7.9% increase from 2025, and a 52.4% increase since 2016.

In the past 10 years, ResMed's cash and equivalents has ranged from $147.13 million in 2019 to $1.47 billion in 2026, and is currently $1.47 billion as of their latest financial filing in 2026.

Over the last 10 years, ResMed's book value per share changed from 12.07 in 2016 to 45.40 in 2026, a change of 276.1%.


Related Companies

Financial statements for NYSE:RMD last updated on 8/13/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel